We measured cyclosporine in whole blood from normal volunteers administered single oral doses of the drug and from two renal-transplant patients on immunosuppressive maintenance therapy, by liquid chromatography (I) and by radioimmunoassay with use of nonspecific polyclonal (II), specific monoclonal (Ill), and nonspecific monoclonal (IV) antibodies. Concentrations determined by Ill were equivalent to I, irrespective of cyclosporine dose, concentration, time after dose, or time after transplant. Concentrations determined by II and IV were consistently higher than those by I, owing to cross reactivity with metabolites. Ratios of values by II and IV to those by I increased from <1.5 to about 3-4 between 0.5 and 12 h after a single cyclosporine dose, owing to differences in rates of appearance and disappearance of cyclosporine and cross-reacting metabolites, though for the constant 12-h dose intervals in the two renal-transplant patients at steady state these ratios (most within the range 3-4) were relatively stable. Ratios of concentrations measured by IV to those by II (mean of 1.2 for single-dose data, most within the range of 1.2 to 1.5 at steady state) were unaffected by time after dose or time after transplant, suggesting that, despite certain cross-reactivity differences between the two nonspecific antibodies, results are proportional throughout therapy. We therefore propose that Ill and IV offer alternatives, respectively, to the currently used I and II for cyclosporine monitoring. recognizing cyclosporine and several of its metabolites. The metabolite products, which arise via Ndemethylation and other oxidative bioconversions of cyclosporine, maintain the cyclic undecapeptide structure of the parent drug (2) and therefore cross react with the polyclonal antibodies that are currently used for radioimmunoassay of the drug (3). The cross reactivity of metabolites in the polyclonal RIA results in two-to fourfold or higher concentration estimates of cyclosporine in patients' blood or plasma as compared with "high-perfonnance" liquid chromatography (HPLC) methods, and this has contributed to the controversy surrounding the choice of methodology for cyclosporine monitoring (4). subject variability in metabolizing capability (5). Even though differences in this ratio may also occur for the same subject during a course of therapy as a result of differential absorption, bioconversion, and clearance rates of the parent drug or metabolites, for measurements taken at equivalent intervals in a stabilized patient at steady state the ratio should be constant (6).
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subject variability in metabolizing capability (5). Even though differences in this ratio may also occur for the same subject during a course of therapy as a result of differential absorption, bioconversion, and clearance rates of the parent drug or metabolites, for measurements taken at equivalent intervals in a stabilized patient at steady state the ratio should be constant (6) .
Accordingly, as the first step in the evaluation of RLA methods employing the specific and nonspecific cyclosporine MAbs for therapeutic monitoring, we serially determined cyclosporine after single oral administrations of the drug at three dose levels for several subjects and compared these "profiles" with proffles obtained with the polyclonal RIA and HPLC assays. Any between-assay differences in measured concentrations as a function of the time after dosing should provide a sensitive index of selectivity differences between the antibodies and HPLC as well as among the antibodies.
To establish the relevance of these selectivity differences in the clinical setting, we also determined cyclosporine concentrations by HPLC, nonspecific polyclonal RIA, and specific and nonspecific MAb RIAs at various times posttransplant in renal-allograft recipients.
Materials and Methods
We determined proffles of cyclosporine concentration in whole blood for 10 normal, healthy men (ages, 18-43 y; mean, 31 y) who received a single dose of 350, 700, and 1400 mg of cyclosporine (Sandimmune Oral Solution; Sandoz Ltd., Basel, Switzerland).
The study design was a replicated 3 x 3 Latin square, with a one-week "washout" interval between doses.Heparinized blood was collected immediately prior to dosing and 0.5, 1,2,3, 4, 6, 8, 12, 24, 48, 72 , and 96 h after each dose. Complete sets of blood specimens were obtained from all 10 subjects. The 390 blood specimens were analyzed by HPLC (7) and by the polyclonal RIA (3). The results of these analyses have been previously reported (6) .
We also analyzed all blood specimens with the specific and nonspecific MAb RIAs (Sandimmune-Kit, Sandoz Ltd.). Before analysis it was verified that no decomposition of cyclosporine or metabolites in blood had occurred during longterm (about three years) storage at -20 #{176}C, as determined by re-analysis of selected specimens spanning a wide concentration range by the polyclonal RIA (data not shown). An interim analysis of these specimens after one year of storage had revealed no decomposition The incubation mixture consisted of reagents identical to those used in the polyclonal RIA with the exception of the antiserum.
We prepared the cyclosporine standards according to the two-step dilution procedure described in the protocol for the polyclonal RIA, but using methanol instead of buffer for the second dilution step. For each subject we constructed a standard curve from data on appropriate dilutions of predose (blank) whole blood supplemented with cyclosporine. All determinations were done in duplicate and calibrators containing known amounts of cyclosporine were co-analyzed in a blind sample protocol to test the reproducibility and accuracy of the MAb analyses.
We also analyzed whole blood obtained from two renalallograft recipients who had received cyclosporine as the primary immunosuppressive agent. Cyclosporine (5 mg/kg per day in two doses given at 12-h intervals) was initiated when the patient had achieved good renal function. The cyclosporine dose was adjusted to maintain a trough (i.e., minimum) cyclosporine concentration in blood in the range of 150 to 400 g/L as determined by the polyclonal RIA method. Concomitant therapy with methylprednisolone was given initially as a 300-mg bolus and then adjusted to 20 mg/day by 30 days post-transplant and 10 mg/day by 60 days. Azathioprine was initiated preoperatively and immediately tapered to 0.75 to 1.0 mg/kg and adjusted if the leukocyte count fell to 5 x i09/L. Whole blood for cyclosporine monitoring was collected just before the evening dose (trough) and was obtained daily while the patient was in the hospital, then less frequently on an outpatient basis in the absence of complications. For the present study, we analyzed blood samples during the first three months post-transplant by HPLC, polyclonal RIA, and the two MAb RIAs. The HPLC method used for analysis of patients' blood specimens has been previously described (9) . The analyses for cyclesporine by the RIA methods were performed on whole blood as described above for the human-volunteer studies. For the comparisons of the analytical methods we employed scatterplots, descriptive statistics, and paired t-tests, and performed regression analysis on concentration data and ratios at different dosages, times post-dose, or time posttransplant.
Results
Accuracy and reproducibility data for the MAb RIA analyses are summarized in Table 1 . We obtained acceptable within-and between-run reproducibility in the course of the analyses, similar to or better than the variability reported for HPLC and polyclonal RIA (10, 11). For both laboratories, assay accuracy was such that any single-use duplicate determination would be within ±23% of the actual concentration at the 95% confidence level. Curves for the mean cyclosporine concentration in the blood of the 10 normal subjects administered single oral doses of the drug are shown in Figure 1 polyclonal RLA. Prior studies of the polyclonal RIA have shown that cross reactivity with metabolites contributes to the large overestimate as compared with HPLC, and the smaller difference in concentration determinations between the polyclonal and nonspecific MAb RIA may also be due to cross reactivity differences (10, 11). The cross reactivity spectra previously elaborated in vitro for the polyclonal (3) and monoclonal (1) antibodies are consistent with our findings. Thus the nonspecific polyclonal and monoclonal antisera both cross react strongly with cyclosporine metabolites no. 1, 8, 17, and 18, although to differing degrees, whereas the specific monoclonal antiserum shows only slight or no cross reactivity with these compounds (1, 3) . Figure 2 compares concentration proffles obtained after a single oral dose of the drug, as measured by HPLC and polyclonal RIA in the present study, with total radioactivity measured in normal volunteers after a single oral dose of radiolabeled cyclosporine (2). The radioactivity curve, which represents concentrations of cyclosporine plus all metabolites, substantially exceeds the values (dose normalized) measured by the polyclonal RIA and, as expected, those measured by HPLC.
Scatterplots of individual data on concentration in whole blood for the 10 subjects (Figure 3 ) reveal a linear correlation for HPLC vs specific MAb RIA ( Figure 3A ) and for polyclonal RIA vs nonspecffic MAb RIA ( Figure 3B) . The increasing scatter of concentrations <100 zg/L may be due to the fact that these approach the limit of detection of the analytical methods as used for the normal volunteer study, of 20-40 p.g/L, 2 mL and 2-2.5 ML aliquots being used for
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Adjustrnentof concentrations is justifiedbydoseproportionality of cyclosponne seen inthis dose range (   HPLC and RIA, respectively (3, 6) . Inspection of residuals for the linear regression plot in Figure 3A reveals that its deviation from unity slope, and therefore the significantly positive intercept, is caused by concentrations >1600 .tg/L. These concentrations gave a response B/B0 of <0.1; that is, they were outside the most-reliable portion of the RIA standard curve. Regression analysis on the concentration data between 0 and 1600 g/L yielded a slope of 0.96 ± 0.01. As expected, in the comparison data for nonspecific MAb RIA vs HPLC ( Figure 3C) , a slope substantially different from unity and a large positive intercept were obtained. Table 2 summarizes Figure 5 , which also summarizes the cyclosporine dose and serum creatiine concentrations during this time period. As was the case for the normal subjects, HPLC profiles are nearly superimposable with those obtained by the specific MAb RIA, while the proffles for the polyclonal RIA and the nonspecific MAb RIA show higher concentration estimates, owing to contributions from the metabolites. Figure 3D shows a scatterplot of the specific MAb RIA vs HPLC data. A slope near unity and zero intercept attests to the good correlation of results by these two methods for patients' blood samples. Table 2 
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HPLC or polyclonal RLA in the blood specimens of normal volunteers given single oral doses of the drug. Figure 2 , however, clearly shows that, after a single oral dose of cyclosporine, cross-reacting metabolites appear, as well as a considerable amount of circulating metabolites that do not cross react appreciably. Perhaps one or more of these metabolites might accumulate to such an extent upon multiple dosing of the drug that cross-reactivity-based differences could become significant and result in discrepancies between the analytical methods. Therefore, substantial equivalence between any two analytical methods must be confirmed in a broad array of patients and clinical situations. Excellent method comparability is demonstrated in our study of serial monitoring of two renal-transplant patients who experienced good renal and hepatic function throughout the study period. It has been shown, however, that the polyclonal RIA vs HPLC ratio can be particularly high in some patients with compromised liver and biiary function-the major excretory mechanism for cyclosporine (12) . Parallel-method studies in cases of impaired liver function, nephrotoxicity, and graft rejection will be necessary to confirm the comparability of the current and new monitoring methods.
The application of MAbs for specific measure of cyclosporme represents an important technical and practical advance in therapeutic monitoring of this potent immunosuppressive agent. Additionally, the combination of the specific and nonspecific MAb RIA methods provides a powerful tool to investigate the influence of metabolism on immunosuppressive therapy and its side effects. We conclude that the good agreement between the analytical methods examined here warrants investigational use of these monitoring methods in a wide array of clinical situations.
